Elicio Therapeutics Announces Publication Of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent And Durable Immune Response In Epstein-Barr Virus Infectious Disease Model
Portfolio Pulse from Benzinga Newsdesk
Elicio Therapeutics (NASDAQ:ELTX) has published preclinical data demonstrating that its AMP-CpG adjuvant can induce a potent and durable immune response to Epstein-Barr virus (EBV). The data shows that AMP-CpG directed the trafficking of the vaccine adjuvant into the lymph node to increase the potency of subunit vaccines for inducing T-cells and neutralizing antibodies. The company's near-term focus remains progressing ELI-002, its cancer vaccine candidate for mutant KRAS-driven solid tumors, through the ongoing phase 1 trials and to a randomized trial in pancreatic cancer in 2024.
August 09, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elicio Therapeutics' preclinical data shows its AMP-CpG adjuvant can induce a potent immune response to Epstein-Barr virus. This could potentially lead to a new vaccine, which would be a significant development for the company.
The publication of preclinical data demonstrating the effectiveness of Elicio's AMP-CpG adjuvant in inducing a potent immune response to EBV is a positive development for the company. This could potentially lead to the development of a new vaccine, which would be a significant milestone for Elicio. This news is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100